In this episode, we are diving deep into the world of the non-coding genome and, more specifically, an exciting new class of biomolecules - the long non-coding RNAs (lncRNA). Welcome, Dr. Samir Ounzain, the co-founder and CEO of HAYA Therapeutics. Samir and his startup HAYA are developing first-in-class therapies to target lncRNA responsible for the manifestation of various diseases. Samir and HAYA are aiming at fibrosis first, but have in mind a plethora of other conditions that can be treated by their approach. Join us for an insightful conversation on the non-coding genome, the journey from basic science to entrepreneurship, and the future of precision therapeutics.

Together with Samir, we discussed:
◦ The founding story of HAYA Therapeutics
◦ The role of non-coding genome in human health
◦ Ability to tweak non-coding genome to treat diseases
◦ Postponing aging using lncRNAs
◦ Impact on the future of precision medicine
◦ Prerequisites for founding a successful biotech company

Get in touch with Samir:
◦ LinkedIn: https://www.linkedin.com/in/samirounzain/
◦ Twitter: @ispiyou
◦ Website: https://www.hayatx.com/

Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com